{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T13:20:46Z","timestamp":1709472046061},"posted":{"date-parts":[[2023,3,2]]},"group-title":"In Review","reference-count":53,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,2,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that regulate gene expression. \u0394<jats:sup>9<\/jats:sup>-tetrahydrocannabinol (\u0394<jats:sup>9<\/jats:sup>-THC) is a PPARg agonist and some endocannabinoids are natural activators of PPAR<jats:italic>a<\/jats:italic> and PPARg. Therefore, both the receptors are putative cannabinoid receptors. However, little is known regarding their cellular distributions in the brain and functional roles in cannabinoid action. Here we first used RNAscope <jats:italic>in situ<\/jats:italic> hybridization and immunohistochemistry assays to examine the cellular distributions of PPAR\u03b1 and PPAR\u03b3 expression in the mouse brain. We found that PPAR\u03b1 and PPAR\u03b3 are highly expressed in ~70% midbrain dopamine (DA) neurons and in ~50% GABAergic and ~50% glutamatergic neurons in the amygdala. However, no PPAR\u03b1\/\u03b3 signal was detected in GABAergic neurons in the nucleus accumbens. We then used a series of behavioral assays to determine the functional roles of PPAR\u03b1\/\u03b3 in the CNS effects of \u0394<jats:sup>9<\/jats:sup>-THC. We found that optogenetic stimulation of midbrain DA neurons was rewarding as assessed by optical intracranial self-stimulation (oICSS) in DAT-cre mice. \u0394<jats:sup>9<\/jats:sup>-THC and a PPAR\u03b3 (but not PPAR\u03b1) agonist dose-dependently inhibited oICSS, suggesting that dopaminergic PPAR\u03b3 modulates DA-dependent behavior. Surprisingly, pretreatment with PPAR\u03b1 or PPAR\u03b3 antagonists dose-dependently attenuated the \u0394<jats:sup>9<\/jats:sup>-THC-induced reduction in oICSS and anxiogenic effects. In addition, a PPAR\u03b3 agonist increased, while PPARa or PPAR\u03b3 antagonists decreased open-field locomotion. Pretreatment with PPARa or PPAR\u03b3 antagonists potentiated \u0394<jats:sup>9<\/jats:sup>-THC-induced hypoactivity and catalepsy but failed to alter \u0394<jats:sup>9<\/jats:sup>-THC-induced analgesia, hypothermia and immobility. These findings provide the first anatomical and functional evidence supporting an important role of PPARa\/g in DA-dependent behavior and cannabinoid action.<\/jats:p>","DOI":"10.21203\/rs.3.rs-2614714\/v1","type":"posted-content","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T19:59:30Z","timestamp":1677787170000},"source":"Crossref","is-referenced-by-count":0,"title":["PPAR\u03b1 and PPAR\u03b3 are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice"],"prefix":"10.21203","author":[{"given":"Zheng-Xiong","family":"Xi","sequence":"first","affiliation":[{"name":"National Institute on Drug Abuse"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Briana","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline","family":"Crissman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sruti","family":"Pari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Hua","family":"Bi","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Alton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"key":"ref1","volume-title":"Results from the 2020 National Survey on Drug Use and Health: Detailed Tables. Substance Abuse and Mental Health Services Administration","author":"SAMHSA","year":"2022","unstructured":"SAMHSA. Results from the 2020 National Survey on Drug Use and Health: Detailed Tables. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Qualty. Rockville, MD. 2022."},{"key":"ref2","unstructured":"NCSL. State Medical Cannabis Laws. National Conference of State Legislatures. Washington, D.C. 2022."},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"E112-E117","DOI":"10.1208\/aapsj080113","article-title":"Activation of G-proteins in brain by endogenous and exogenous cannabinoids","volume":"8","author":"Childers SR","year":"2006","unstructured":"Childers SR. Activation of G-proteins in brain by endogenous and exogenous cannabinoids. The AAPS Journal 2006; 8(1): E112-E117.","journal-title":"The AAPS Journal"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/b137831","volume-title":"Cannabinoids","author":"Pertwee RG","year":"2005","unstructured":"Pertwee RG. Pharmacological Actions of Cannabinoids. In: Pertwee RG (ed). Cannabinoids. Springer Berlin Heidelberg: Berlin, Heidelberg, 2005, pp\u00a01\u201351."},{"key":"ref5","unstructured":"Advances in pharmacology (San Diego, Calif) 2022; 93: 275\u2013333."},{"key":"ref6","author":"Howlett AC","year":"2017","unstructured":"Howlett AC, Abood ME. Chapter Five - CB1 and CB2 Receptor Pharmacology. In: Kendall D, Alexander SPH (eds). Advances in Pharmacology, vol.\u00a080. Academic Press2017, pp\u00a0169\u2013206."},{"key":"ref7","first-page":"115","article-title":"Known pharmacological actions of delta-9-tetrahydrocannabinol and of four other chemical constituents of cannabis that activate cannabinoid receptors","volume":"2014","author":"Pertwee RG","unstructured":"Pertwee RG, Cascio MG. Known pharmacological actions of delta-9-tetrahydrocannabinol and of four other chemical constituents of cannabis that activate cannabinoid receptors. Handbook of cannabis 2014: 115.","journal-title":"Handbook of cannabis"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee RG","year":"2008","unstructured":"Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology 2008; 153(2): 199\u2013215.","journal-title":"British journal of pharmacology"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/bph.14339","article-title":"PPARs and pain","volume":"176","author":"Okine BN","year":"2019","unstructured":"Okine BN, Gaspar JC, Finn DP. PPARs and pain. British Journal of Pharmacology 2019; 176(10): 1421\u20131442.","journal-title":"British Journal of Pharmacology"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"964","DOI":"10.2174\/1568026621666210521165532","article-title":"The Role of Peroxisome Proliferator-Activated Receptor in Addiction: A Novel Drug Target","volume":"21","author":"Quiroga C","year":"2021","unstructured":"Quiroga C, Barberena JJ, Alcaraz-Silva J, Machado S, Imperatori C, Yadollahpour A et al. The Role of Peroxisome Proliferator-Activated Receptor in Addiction: A Novel Drug Target. Current Topics in Medicinal Chemistry 2021; 21(11): 964\u2013975.","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular Actions of PPAR\u03b1 in Lipid Metabolism and Inflammation","volume":"39","author":"Bougarne N","year":"2018","unstructured":"Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B et al. Molecular Actions of PPAR\u03b1 in Lipid Metabolism and Inflammation. Endocr Rev 2018; 39(5): 760\u2013802.","journal-title":"Endocr Rev"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.2042-7158.2011.01432.x","article-title":"PPAR\u03b3 agonist pioglitazone improves scopolamine-induced memory impairment in mice","volume":"64","author":"Xiang GQ","year":"2012","unstructured":"Xiang GQ, Tang SS, Jiang LY, Hong H, Li Q, Wang C et al. PPAR\u03b3 agonist pioglitazone improves scopolamine-induced memory impairment in mice. Journal of Pharmacy and Pharmacology 2012; 64(4): 589\u2013596.","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/npp.2014.268","article-title":"PPAR\u03b3 Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission","volume":"40","author":"Guglielmo G","year":"2015","unstructured":"de Guglielmo G, Melis M, De Luca MA, Kallupi M, Li HW, Niswender K et al. PPAR\u03b3 Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission. Neuropsychopharmacology 2015; 40(4): 927\u2013937.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.biopsych.2010.07.009","article-title":"Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors","volume":"69","author":"Mascia P","year":"2011","unstructured":"Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S et al. Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors. Biological Psychiatry 2011; 69(7): 633\u2013641.","journal-title":"Biological Psychiatry"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.biopsych.2010.12.010","article-title":"Activation of nuclear PPAR\u03b3 receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking","volume":"69","author":"Stopponi S","year":"2011","unstructured":"Stopponi S, Somaini L, Cippitelli A, Cannella N, Braconi S, Kallupi M et al. Activation of nuclear PPAR\u03b3 receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry 2011; 69(7): 642\u2013649.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.npp.1301213","article-title":"Peroxisome Proliferator-Activated Receptor Gamma Activation Relieves Expression of Behavioral Sensitization to Methamphetamine in Mice","volume":"32","author":"Maeda T","year":"2007","unstructured":"Maeda T, Kiguchi N, Fukazawa Y, Yamamoto A, Ozaki M, Kishioka S. Peroxisome Proliferator-Activated Receptor Gamma Activation Relieves Expression of Behavioral Sensitization to Methamphetamine in Mice. Neuropsychopharmacology 2007; 32(5): 1133\u20131140.","journal-title":"Neuropsychopharmacology"},{"issue":"24","key":"ref17","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1111\/bph.13352","article-title":"The Concise Guide to PHARMACOLOGY 2015\/16: Nuclear hormone receptors","volume":"172","author":"Alexander SP","year":"2015","unstructured":"Alexander SP, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE et al. The Concise Guide to PHARMACOLOGY 2015\/16: Nuclear hormone receptors. British Journal of Pharmacology 2015; 172(24): 5956\u20135978.","journal-title":"British Journal of Pharmacology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger J","year":"2002","unstructured":"Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409\u2013435.","journal-title":"Annu Rev Med"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi S","year":"2011","unstructured":"Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. Journal of advanced pharmaceutical technology & research 2011; 2(4): 236\u2013240.","journal-title":"Journal of advanced pharmaceutical technology & research"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjp.0707478","article-title":"Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism","volume":"152","author":"Sun Y","year":"2007","unstructured":"Sun Y, Alexander SPH, Garle MJ, Gibson CL, Hewitt K, Murphy SP et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. British journal of pharmacology 2007; 152(5): 734\u2013743.","journal-title":"British journal of pharmacology"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"et al. 15-Lipoxygenase Metabolism of 2-Arachidonylglycerol: GENERATION OF A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR \u03b1 AGONIST *. Journal of Biological Chemistry 2002; 277(26): 23278\u201323286.","DOI":"10.1074\/jbc.M201084200"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.neuropharm.2012.05.013","article-title":"WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-\u03b3 pathway","volume":"63","author":"Fakhfouri G","year":"2012","unstructured":"Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-\u03b3 pathway. Neuropharmacology 2012; 63(4): 653\u2013666.","journal-title":"Neuropharmacology"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejphar.2005.05.032","article-title":"Anandamide induced PPAR\u03b3 transcriptional activation and 3T3-L1 preadipocyte differentiation","volume":"517","author":"Bouaboula M","year":"2005","unstructured":"Bouaboula M, Hilairet S, Marchand J, Fajas L, Fur GL, Casellas P. Anandamide induced PPAR\u03b3 transcriptional activation and 3T3-L1 preadipocyte differentiation. European Journal of Pharmacology 2005; 517(3): 174\u2013181.","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1124\/mol.105.019117","article-title":"Interleukin-2 Suppression by 2-Arachidonyl Glycerol Is Mediated through Peroxisome Proliferator-Activated Receptor \u03b3 Independently of Cannabinoid Receptors 1 and 2","volume":"70","author":"Rockwell CE","year":"2006","unstructured":"Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE. Interleukin-2 Suppression by 2-Arachidonyl Glycerol Is Mediated through Peroxisome Proliferator-Activated Receptor \u03b3 Independently of Cannabinoid Receptors 1 and 2. Molecular Pharmacology 2006; 70(1): 101\u2013111.","journal-title":"Molecular Pharmacology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tox.2014.09.011","article-title":"\u22069-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: Possible involvement of induced levels of PPAR\u03b1 in MDA-MB-231 breast cancer cells","volume":"326","author":"Takeda S","year":"2014","unstructured":"Takeda S, Ikeda E, Su S, Harada M, Okazaki H, Yoshioka Y et al. \u22069-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: Possible involvement of induced levels of PPAR\u03b1 in MDA-MB-231 breast cancer cells. Toxicology 2014; 326: 18\u201324.","journal-title":"Toxicology"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2990.2011.01248.x","article-title":"\u22069-tetrahydrocannabinol (\u22069-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease","volume":"38","author":"Carroll CB","year":"2012","unstructured":"Carroll CB, Zeissler M-L, Hanemann CO, Zajicek JP. \u22069-tetrahydrocannabinol (\u22069-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathology and Applied Neurobiology 2012; 38(6): 535\u2013547.","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bbrc.2005.09.121","article-title":"Novel time-dependent vascular actions of \u22069-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma","volume":"337","author":"O\u2019Sullivan SE","year":"2005","unstructured":"O\u2019Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD. Novel time-dependent vascular actions of \u22069-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochemical and Biophysical Research Communications 2005; 337(3): 824\u2013831.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"e618-e618","DOI":"10.1038\/cddis.2013.141","article-title":"Involvement of PPAR\u03b3 in the antitumoral action of cannabinoids on hepatocellular carcinoma","volume":"4","author":"Vara D","year":"2013","unstructured":"Vara D, Morell C, Rodr\u00edguez-Henche N, Diaz-Laviada I. Involvement of PPAR\u03b3 in the antitumoral action of cannabinoids on hepatocellular carcinoma. Cell death & disease 2013; 4(5): e618-e618.","journal-title":"Cell death & disease"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"27618","DOI":"10.1038\/srep27618","article-title":"Localization of PPAR isotypes in the adult mouse and human brain","volume":"6","author":"Warden A","year":"2016","unstructured":"Warden A, Truitt J, Merriman M, Ponomareva O, Jameson K, Ferguson LB et al. Localization of PPAR isotypes in the adult mouse and human brain. Scientific Reports 2016; 6(1): 27618.","journal-title":"Scientific Reports"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"107597","DOI":"10.1016\/j.neuropharm.2019.04.003","article-title":"The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents","volume":"158","author":"Jordan CJ","year":"2019","unstructured":"Jordan CJ, Humburg B, Rice M, Bi G-H, You Z-B, Shaik AB et al. The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents. Neuropharmacology 2019; 158: 107597.","journal-title":"Neuropharmacology"},{"issue":"46","key":"ref31","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1523\/JNEUROSCI.0988-20.2020","article-title":"Dissecting the Role of GABA Neurons in the VTA versus SNr in Opioid Reward","volume":"40","author":"Galaj E","year":"2020","unstructured":"Galaj E, Han X, Shen H, Jordan CJ, He Y, Humburg B et al. Dissecting the Role of GABA Neurons in the VTA versus SNr in Opioid Reward. J Neurosci 2020; 40(46): 8853\u20138869.","journal-title":"J Neurosci"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"e13005","DOI":"10.1111\/adb.13005","article-title":"Optogenetic brain-stimulation reward: A new procedure to re-evaluate the rewarding versus aversive effects of cannabinoids in dopamine transporter-Cre mice","volume":"26","author":"Humburg BA","year":"2021","unstructured":"Humburg BA, Jordan CJ, Zhang H-Y, Shen H, Han X, Bi G-H et al. Optogenetic brain-stimulation reward: A new procedure to re-evaluate the rewarding versus aversive effects of cannabinoids in dopamine transporter-Cre mice. Addiction Biology 2021; 26(4): e13005.","journal-title":"Addiction Biology"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","author":"O'Sullivan SE","year":"2016","unstructured":"O'Sullivan SE. An update on PPAR activation by cannabinoids. British Journal of Pharmacology 2016; 173(12): 1899\u20131910.","journal-title":"British Journal of Pharmacology"},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice","volume":"14","author":"Xi ZX","year":"2011","unstructured":"Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR et al. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci 2011; 14(9): 1160\u20131166.","journal-title":"Nat Neurosci"},{"issue":"46","key":"ref35","doi-asserted-by":"crossref","first-page":"E5007-5015","DOI":"10.1073\/pnas.1413210111","article-title":"Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice","volume":"111","author":"Zhang HY","year":"2014","unstructured":"Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ et al. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A 2014; 111(46): E5007-5015.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1523\/JNEUROSCI.1493-22.2022","article-title":"Cannabinoid CB1 Receptors Are Expressed in a Subset of Dopamine Neurons and Underlie Cannabinoid-Induced Aversion, Hypoactivity, and Anxiolytic Effects in Mice","volume":"43","author":"Han X","year":"2023","unstructured":"Han X, Liang Y, Hempel B, Jordan CJ, Shen H, Bi GH et al. Cannabinoid CB1 Receptors Are Expressed in a Subset of Dopamine Neurons and Underlie Cannabinoid-Induced Aversion, Hypoactivity, and Anxiolytic Effects in Mice. J Neurosci 2023; 43(3): 373\u2013385.","journal-title":"J Neurosci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"108538","DOI":"10.1016\/j.neuropharm.2021.108538","article-title":"Cannabinoid CB(2) receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice","volume":"189","author":"Zhang HY","year":"2021","unstructured":"Zhang HY, Shen H, Gao M, Ma Z, Hempel BJ, Bi GH et al. Cannabinoid CB(2) receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice. Neuropharmacology 2021; 189: 108538.","journal-title":"Neuropharmacology"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40263-019-00664-w","article-title":"Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders","volume":"33","author":"Galaj E","year":"2019","unstructured":"Galaj E, Xi Z-X. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. CNS Drugs 2019; 33(10): 1001\u20131030.","journal-title":"CNS Drugs"},{"issue":"S1","key":"ref39","doi-asserted-by":"crossref","first-page":"S163-S171","DOI":"10.1038\/sj.bjp.0706406","article-title":"Cannabinoid pharmacology: the first 66 years","volume":"147","author":"Pertwee RG","year":"2006","unstructured":"Pertwee RG. Cannabinoid pharmacology: the first 66 years. British Journal of Pharmacology 2006; 147(S1): S163-S171.","journal-title":"British Journal of Pharmacology"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/bph.14625","article-title":"Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats","volume":"176","author":"Spiller KJ","year":"2019","unstructured":"Spiller KJ, Bi G-h, He Y, Galaj E, Gardner EL, Xi Z-X. Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats. British Journal of Pharmacology 2019; 176(9): 1268\u20131281.","journal-title":"British Journal of Pharmacology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.euroneuro.2020.11.019","article-title":"Dissecting the role of CB1 and CB2 receptors in cannabinoid reward versus aversion using transgenic CB1- and CB2-knockout mice","volume":"43","author":"Li X","year":"2021","unstructured":"Li X, Hempel BJ, Yang H-J, Han X, Bi G-H, Gardner EL et al. Dissecting the role of CB1 and CB2 receptors in cannabinoid reward versus aversion using transgenic CB1- and CB2-knockout mice. European Neuropsychopharmacology 2021; 43: 38\u201351.","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"12315","DOI":"10.1038\/s41598-017-12399-z","article-title":"CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies \u22069-Tetrahydrocannabinol (\u22069-THC)-Induced Aversive Effects in Mice","volume":"7","author":"Han X","year":"2017","unstructured":"Han X, He Y, Bi G-H, Zhang H-Y, Song R, Liu Q-R et al. CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies \u22069-Tetrahydrocannabinol (\u22069-THC)-Induced Aversive Effects in Mice. Scientific Reports 2017; 7(1): 12315.","journal-title":"Scientific Reports"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neuroscience.2004.09.043","article-title":"Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons","volume":"130","author":"Cimini A","year":"2005","unstructured":"Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico MA, D'Angelo B et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 2005; 130(2): 325\u2013337.","journal-title":"Neuroscience"},{"issue":"50","key":"ref44","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1523\/JNEUROSCI.4127-15.2016","article-title":"Genetic Deletion of Neuronal PPAR\u03b3 Enhances the Emotional Response to Acute Stress and Exacerbates Anxiety: An Effect Reversed by Rescue of Amygdala PPAR\u03b3 Function","volume":"36","author":"Domi E","year":"2016","unstructured":"Domi E, Uhrig S, Soverchia L, Spanagel R, Hansson AC, Barbier E et al. Genetic Deletion of Neuronal PPAR\u03b3 Enhances the Emotional Response to Acute Stress and Exacerbates Anxiety: An Effect Reversed by Rescue of Amygdala PPAR\u03b3 Function. The Journal of Neuroscience 2016; 36(50): 12611\u201312623.","journal-title":"The Journal of Neuroscience"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/npp.2012.123","article-title":"Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission","volume":"37","author":"Rey AA","year":"2012","unstructured":"Rey AA, Purrio M, Viveros M-P, Lutz B. Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission. Neuropsychopharmacology 2012; 37(12): 2624\u20132634.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"15025","DOI":"10.1038\/s41598-017-14203-4","article-title":"Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors","volume":"7","author":"Bhattacharyya S","year":"2017","unstructured":"Bhattacharyya S, Egerton A, Kim E, Rosso L, Riano Barros D, Hammers A et al. Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors. Scientific Reports 2017; 7(1): 15025.","journal-title":"Scientific Reports"},{"issue":"49","key":"ref47","doi-asserted-by":"crossref","first-page":"9864","DOI":"10.1523\/JNEUROSCI.1922-19.2019","article-title":"Activation of PPAR\u03b3 Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission","volume":"39","author":"Domi E","year":"2019","unstructured":"Domi E, Caputi FF, Romualdi P, Domi A, Scuppa G, Candeletti S et al. Activation of PPAR\u03b3 Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission. The Journal of Neuroscience 2019; 39(49): 9864\u20139875.","journal-title":"The Journal of Neuroscience"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pbb.2015.05.002","article-title":"Measures of the aversive effects of drugs: A comparison of conditioned taste and place aversions","volume":"134","author":"Gore-Langton JK","year":"2015","unstructured":"Gore-Langton JK, Flax SM, Pomfrey RL, Wetzell BB, Riley AL. Measures of the aversive effects of drugs: A comparison of conditioned taste and place aversions. Pharmacology, Biochemistry and Behavior 2015; 134: 99\u2013105.","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"3\u20134","key":"ref49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1369-1600.2007.00070.x","article-title":"Measuring reward with the conditioned place preference (CPP) paradigm: Update of the last decade","volume":"12","author":"Tzschentke TM","year":"2007","unstructured":"Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: Update of the last decade. Addiction Biology 2007; 12(3\u20134): 227\u2013462.","journal-title":"Addiction Biology"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/npp.2012.100","article-title":"Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans","volume":"37","author":"Dlugos A","year":"2012","unstructured":"Dlugos A, Childs E, Stuhr KL, Hillard CJ, de Wit H. Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 2012; 37(11): 2416\u20132427.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1210\/en.2011-1689","article-title":"Physiological Responses to Acute Psychological Stress Are Reduced by the PPAR\u03b3 Agonist Rosiglitazone","volume":"153","author":"Ryan KK","year":"2012","unstructured":"Ryan KK, Grayson BE, Jones KR, Schneider AL, Woods SC, Seeley RJ et al. Physiological Responses to Acute Psychological Stress Are Reduced by the PPAR\u03b3 Agonist Rosiglitazone. Endocrinology 2012; 153(3): 1279\u20131287.","journal-title":"Endocrinology"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/15569543.2019.1673425","article-title":"The effects of PPAR-\u03b3 agonist pioglitazone on anxiety and depression-like behaviors in lipopolysaccharide injected rats","volume":"40","author":"Beheshti F","year":"2021","unstructured":"Beheshti F, Hosseini M, Hashemzehi M, Soukhtanloo M, Asghari A. The effects of PPAR-\u03b3 agonist pioglitazone on anxiety and depression-like behaviors in lipopolysaccharide injected rats. Toxin Reviews 2021; 40(4): 1223\u20131232.","journal-title":"Toxin Reviews"},{"issue":"9","key":"ref53","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/cns.12137","article-title":"Effect of rosiglitazone, a PPAR-\u03b3 ligand on haloperidol-induced catalepsy","volume":"19","author":"Gupta G","year":"2013","unstructured":"Gupta G, Singh R, David SR, Verma RK. Effect of rosiglitazone, a PPAR-\u03b3 ligand on haloperidol-induced catalepsy. CNS Neurosci Ther 2013; 19(9): 724\u2013725.","journal-title":"CNS Neurosci Ther"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2614714\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2614714\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T07:06:56Z","timestamp":1690009616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2614714\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":53,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2614714\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41380-023-02182-0","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,3,2]]},"subtype":"preprint"}}